Introduction {#s1}
============

Lung cancer is the most commonly occurring cancer worldwide. In the USA and the UK it is the second most incident cancer [@pmed.1001376-Cancer1],[@pmed.1001376-Howlader1], as well as the most common cause of cancer mortality [@pmed.1001376-Howlader1],[@pmed.1001376-Cancer2]. Survival differs internationally. In the UK, fewer than 10% of those diagnosed with lung cancer survive for 5 years [@pmed.1001376-Cancer2],[@pmed.1001376-Coleman1], with higher survival rates found in Nordic countries [@pmed.1001376-Coleman1],[@pmed.1001376-Verdecchia1], the USA [@pmed.1001376-Howlader1],[@pmed.1001376-Verdecchia1], Australia, and Canada [@pmed.1001376-Coleman1].

Lung cancers are classified into small cell (SCLC) and non-small cell (NSCLC) lung cancers. NSCLC is more common than SCLC and has a better survival rate [@pmed.1001376-NICE1]. National Institute for Health and Clinical Excellence (NICE) guidelines recommend radical surgery for stage I or II NSCLC [@pmed.1001376-NICE1]. Chemotherapy and radiotherapy are recommended for later-stage NSCLC patients and are the treatments of choice for SCLC [@pmed.1001376-NICE1]. Treatment intervention with surgery, chemotherapy, or radiotherapy has been shown to improve lung cancer survival [@pmed.1001376-NICE1].

Socioeconomic inequalities in incidence of, and survival from, the majority of cancers have been reported [@pmed.1001376-Cancer1],[@pmed.1001376-Cancer2],[@pmed.1001376-Rachet1]. A recent non-systematic review revealed socioeconomic inequalities in receipt of treatment for colorectal cancer [@pmed.1001376-Aarts1], and it has been suggested that socioeconomic differences in access to treatment might at least partially explain socioeconomic differences in survival [@pmed.1001376-Woods1]. Unintended variations in outcome that result from the way that health interventions are organised and delivered have been described as intervention-generated inequalities [@pmed.1001376-White1].

Incidence of lung cancer is higher [@pmed.1001376-Cancer1],[@pmed.1001376-Sidorchuk1], and survival poorer [@pmed.1001376-Rachet1], in the most deprived patient groups. However, it is not known whether socioeconomic inequalities in receipt of treatment exist for lung cancer and, if so, what contribution they make to overall socioeconomic inequalities in outcome. In order to explore the first of these questions, we undertook a systematic review and meta-analysis of cohort studies examining the association between socioeconomic position (SEP) and receipt of lung cancer treatment.

Methods {#s2}
=======

A protocol (see [Text S2](#pmed.1001376.s012){ref-type="supplementary-material"}) was developed and systematic methods were used to identify relevant studies, assess study eligibility for inclusion, and evaluate study quality. The review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [@pmed.1001376-Moher1] (see [Text S1](#pmed.1001376.s011){ref-type="supplementary-material"} for PRISMA checklist).

Literature Search {#s2a}
-----------------

The online databases of MEDLINE and EMBASE were searched up to September 2012 (see [Table S1](#pmed.1001376.s010){ref-type="supplementary-material"} for full search strategies). No language restriction was applied. A search of Scopus uncovered no further papers. Additional studies were identified by reviewing the reference lists of all included studies and by using a forward citation search to identify more recent studies that had cited included studies. EndNote X5 software was used to manage the references.

Study Eligibility {#s2b}
-----------------

Studies that met the following criteria were included in the review: primary, cohort studies of participants with a primary diagnosis of lung cancer (ICD10 C33 or C34) reported separately from other cancers; published in a peer-reviewed journal; where at least one reported outcome was receipt of treatment (measured by rates or odds of receiving treatment); and where receipt of this outcome was reported by a measure of SEP. Any curative or palliative treatment for lung cancer including surgery, chemotherapy, and radiotherapy was included.

Studies where SEP was included as a descriptive variable or confounder, but where outcomes for receipt of treatment by SEP were not presented, were not eligible for inclusion, but the authors were contacted to determine whether relevant data were available that might allow for inclusion in the review.

Studies where multivariable analysis was conducted (and included control for a minimum of age and sex as confounders); receipt of treatment was compared to not receiving treatment; odds ratios (ORs) and 95% confidence intervals (CIs) of receipt of treatment in low compared to high SEP were calculated; and SEP was not further stratified by another variable, were considered suitable for inclusion in meta-analysis.

Acceptable measures of SEP were: area-based indices of deprivation (e.g., Index of Multiple Deprivation \[IMD\], Townsend Score, Carstairs Index); and area or individual measures of income, poverty, or education level.

Multiple papers using the same or overlapping study data were included. Sensitivity analyses were conducted including all eligible papers and using different combinations of included papers, but only data from the better quality or more detailed paper in each overlapping study group were included in the final meta-analyses. Sensitivity meta-analyses are included in the supplemental material.

Study Selection and Data Extraction {#s2c}
-----------------------------------

Studies obtained from the database searches were independently assessed by two researchers (LFF and HW) in three phases: title, abstract, and full paper screening. Any disagreements at any of the screening stages were resolved by discussion between the two researchers in the first instance and with a third reviewer (JA) if agreement could not be reached. Data extraction was carried out by LFF using an Access database pro-forma developed for this purpose, and double-checked by HW.

There is evidence to suggest that health insurance status is an important factor relating to access to lung cancer care in countries such as the USA that rely on insurance-based health care systems [@pmed.1001376-Slatore1]. Insurance status is less relevant and rarely measured in most other countries. Therefore, three analytical categories were developed a priori: studies conducted in a universal health care system (UHCS), free at the point of access (similar to the UK); studies conducted in countries with primarily private insurance health care systems (non-UHCS, similar to the USA) [@pmed.1001376-Donaldson1]; and studies conducted in countries with social insurance health care systems (similar to many European countries). No studies were identified that fell into the third category.

Study Quality {#s2d}
-------------

A study quality tool, adapted from existing quality tools [@pmed.1001376-SIGN1],[@pmed.1001376-Vandenbroucke1], was used to divide studies into six quality categories, with 1 being the lowest, and 6 the highest, quality (see [Text S3](#pmed.1001376.s013){ref-type="supplementary-material"}). Quality assessment was carried out by LFF and checked by HW.

Cohort studies reporting only univariable analysis are of lower quality in terms of their ability to control for confounding. Only studies conducting multivariable analysis (quality scores 3--6) were included in the meta-analysis. All studies that met the inclusion criteria were analysed in the narrative synthesis.

Statistical Analysis {#s2e}
--------------------

Trends in receipt of treatment across SEP groups were described in the narrative analysis of all studies that met the inclusion criteria.

Meta-analysis of eligible studies was undertaken using Cochrane Collaboration Review Manager 5.1. Natural logs of the ORs and their standard errors (SEs) were calculated for use in forest plots. Random-effects meta-analysis of the odds of treatment in the lowest compared to the highest SEP group was conducted. Where a study reported the most deprived class as the comparator, reverse ORs were calculated. Studies that presented a single OR as either an OR for a one unit increase in deprivation score or incremental quintile increase in income were not included.

Subgroup analyses by treatment type and health care system were conducted. In meta-analyses where a "substantial" percentage [@pmed.1001376-The1] of the variability appeared to be due to the heterogeneity of the studies rather than to chance, further subgroup analyses by stage, histology, and quality score were conducted, where appropriate, in order to examine potential sources of heterogeneity. A funnel plot was used to assess potential publication bias.

Results {#s3}
=======

Included Papers/Studies {#s3a}
-----------------------

A total of 46 papers met the inclusion criteria and were included in the review (see the PRISMA flow diagram \[[Figure 1](#pmed-1001376-g001){ref-type="fig"}\]). Twenty-eight papers were from UHCS countries ([Tables 1](#pmed-1001376-t001){ref-type="table"} and [2](#pmed-1001376-t002){ref-type="table"}). Of these, 19 UK papers examined 13 study populations, although as these included national and regional populations from different sources, there was some further population overlap. One UK paper also compared treatment in Scotland and Canada [@pmed.1001376-Erridge1]. A further nine papers from Canada (2), Sweden (1), Australia (1), Italy (1), France (1), and New Zealand (3) were included. The three New Zealand papers all examined the same population.

![Flow diagram of study selection and exclusion.\
CI, confidence interval; SEP, socioeconomic position.](pmed.1001376.g001){#pmed-1001376-g001}

10.1371/journal.pmed.1001376.t001

###### Characteristics of included studies potentially suitable for meta-analysis (universal health care systems).

![](pmed.1001376.t001){#pmed-1001376-t001-1}

  Paper                                              Country of Study                                                 Data Source (s)                                                                      Population Included                        Years of Diagnosis                   Measure of SEP                                 No. of SEP groups                Treatment given within   Age Range    Confounders Controlled For:   Quality Score                                                                                                                                                                    
  ------------------------------------------------- ------------------ -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------- ------------------------------------------------- --------------------------------------------- ------------------------ ------------ ----------------------------- --------------- ----- ----- ----------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------
  Berglund et al, 2010 [@pmed.1001376-Berglund1]          Sweden        Regional Lung Cancer Register (RLCR) - Sweden, Cause of Death Register and LISA (insurance and demographics)             Uppsala/Orebro region in central Sweden                  1996--2004       Education level[a](#nt102){ref-type="table-fn"}                        3                                  NR                30+                   Yes                    Yes        Yes   Yes                                                  Performance status, year of diagnosis, smoking status                                                                   6
  Berglund et al, 2012 [@pmed.1001376-Berglund2]         England                                            Thames Cancer Registry, HES, LUCADA                                                             South-east England                            2006--2008                   IMD 2007 income domain                                     5                                  NR               0--80+                 Yes                    Yes        Yes   Yes                                                                      Co-morbidity                                                                                        6
  Campbell et al, 2002 [@pmed.1001376-Campbell1]         Scotland                                     Scottish Cancer Registry and hospital case notes                                 Random sample from North/NE Scotland (with hospital record)        1995--1996                       Carstairs Index                                        5                              12 months              NR                   Yes                    Yes        Yes   Yes                                               Health board, distance to cancer centre, mode of admission                                                                 5
  Crawford et al, 2009 [@pmed.1001376-Crawford1]         England                          Northern and Yorkshire Cancer Registry and Information Service (NYCRIS)                                     Northern and Yorkshire region                       1994--2002        IMD 2004 (access to services domain removed)                          4                               6 months              NR                   Yes                    Yes        No    Yes         Travel time (but overall results not stratified by travel time used here). Histology not included in receipt of any treatment analysis.                          4
  Erridge et al, 2002 [@pmed.1001376-Erridge2]           Scotland                                       Scottish Cancer Registry and medical records                                                 Scotland (with hospital record)                         1995                          Carstairs Index                                        5                               6 months          \<60-- 80+               Yes                    Yes        Yes   Yes                          Health board (not inc in receipt of radiotherapy), diagnosis by specialist, management by oncologist                                            6
  Erridge et al, 2009 [@pmed.1001376-Erridge1]       Scotland/Canada                   Scottish Cancer Registry and medical records; British Columbia Cancer Registry                                   Scotland/British Columbia                            1995             Carstairs Index/average household income                            2                               6 months          \<60-- 80+               Yes                    Yes        Yes   Yes                                                                  Travel time, CT scan                                                                                    4
  Gregor et al, 2001 [@pmed.1001376-Gregor1]             Scotland                                       Scottish Cancer Registry and medical records                                                 Scotland (with hospital record)                         1995                          Carstairs Index                                        5                               6 months          \<60--80+                Yes                    Yes        Yes   Yes                                                   Referral to specialist within 6 months of diagnosis                                                                    6
  Jack et al, 2003 [@pmed.1001376-Jack1]                 England                                                   Thames Cancer Registry                                                                   South-east England                            1995--1999        Townsend (median score per health authority)     Contin-uous[b](#nt103){ref-type="table-fn"}             NR             \<35--85+                Yes                    Yes        Yes   Yes   First hospital visited is a radiotherapy centre, basis of diagnosis, incidence. Health authority/hospital used as 2^nd^ level in multi-level model.                    4
  Jack et al, 2006 [@pmed.1001376-Jack2]                 England                                         Thames Cancer Registry and medical records                                              South-east London (with hospital record)                    1998                             IMD 2000                                            5                               6 months          \<55--85+                Yes                    Yes        Yes   Yes                                Consultant specialty, basis of diagnosis (hospital, number of symptoms in some analyses)                                                  6
  Jones et al,2008 [@pmed.1001376-Jones1]                England                          Northern and Yorkshire Cancer Registry and Information Service (NYCRIS)                                     Northern and Yorkshire region                       1994--2002        IMD 2004 (access to services domain removed)     Contin-uous[c](#nt104){ref-type="table-fn"}             NR                 NR                   Yes                    Yes        No    Yes                                                                 Travel time to hospital                                                                                  4
  Mahmud et al, 2003 [@pmed.1001376-Mahmud1]             Ireland                                         National Cancer Registry of Ireland (NCRI)                                                        Republic of Ireland                            1994--1998         SAHRU area-based material deprivation index                          3                               6 months           15--80+                 Yes                    Yes        No    Yes                                                             Health board, year of diagnosis                                                             4/2[d](#nt105){ref-type="table-fn"}
  McMahon et al, 2011 [@pmed.1001376-McMahon1]           England                                   Eastern Cancer Registry and Information Centre (ECRIC)                                                    East of England                              1995--2006        IMD 2004 (access to services domain removed)                          5                                  NR             \<60--80+                Yes                    Yes        No    Yes                                                                    Year of diagnosis                                                                                     4
  Pollock &Vickers, 1998 [@pmed.1001376-Pollock1]        England                                                          HES FCEs                                                              North/South Thames (admitted to hospital)                 1992--1995                          Townsend                                           10                                  NR               \<100                  Yes                    Yes        No    No                                                                Hospital, mode of admission                                                                                3
  Raine et al, 2010 [@pmed.1001376-Raine1]               England                                                          HES FCEs                                                                    England (admitted to hospital)                      1999--2006                             IMD                                              5                                  NR              50-- 90+                Yes                    Yes        No    No                                                        Trust, year of admission, mode of admission                                                                        3
  Riaz et al, 2012 [@pmed.1001376-Riaz1]                 England                                                NCIN/UKACR cancer registries                                                                     England                                  2004--2006                          IMD 2004                                            5                                  NR              0-- 85+                 Yes                    Yes        No    No                                                                 Government Office Region                                                                                  4
  Rich et al, 2011(1) [@pmed.1001376-Rich2]              England                                             LUCADA supplied by 157 NHS trusts                                                                   England                                  2004--2007                          Townsend                                            5                                  NR                 NR                   Yes                    Yes        Yes   Yes                                                Performance status. Adjusted for clustering by NHS trust                                                                  5
  Rich et al, 2011(2) [@pmed.1001376-Rich1]              England                                                       LUCADA and HES                                                                            England                                  2004--2008                          Townsend                                            5                                  NR              30--100                 Yes                    Yes        Yes   Yes                     Co-morbidity, ethnicity, surgery centre, radiotherapy centre, trial entry. Adjusted for clustering by NHS trust                                      5
  Stevens et al, 2007 [@pmed.1001376-Stevens1]         New Zealand                      Regional hospital and oncology databases checked against NZ cancer registry                    Auckland-Northland region patients managed in secondary care          2004                       NZ Deprivation Index                                      2                                  NR             \<60--80+                Yes                    Yes        Yes   Yes                                                Co-morbidity, private sector care, care discussed at MDM                                                                  3
  Stevens et al, 2008 [@pmed.1001376-Stevens2]         New Zealand                      Regional hospital and oncology databases checked against NZ cancer registry                    Auckland-Northland region patients managed in secondary care          2004                       NZ Deprivation Index                                     10                                  NR             \<60--80+                Yes                    Yes        Yes   Yes                                                      Co-morbidity, private sector care, ethnicity                                                                        5

Quality score ranges from 1 (lowest quality) to 6 (highest quality).

Socioeconomic index (SEI) and household income also measured but individual education level used in analyses as it contained least missing data.

Odds ratio for 1 unit increase in deprivation score, range unknown.

Odds ratio for 1 unit increase in deprivation score, range 1--80.

Quality score 4 where adjusted OR used and 2 where unadjusted rates used.

HES, Hospital Episode Statistics; HES FCE, Hospital Episode Statistics Finished Consultant Episode; IMD, Index of Multiple Deprivation; LUCADA, Lung Cancer Audit; MDM, multi-disciplinary meeting; NCIN/UKACR, National Cancer Information Network/UK Association of Cancer Registries; NR, not reported; OR, odds ratio; SEP, socioeconomic position; UHCS, universal health care system.

10.1371/journal.pmed.1001376.t002

###### Characteristics of included studies not suitable for meta-analysis (universal health care systems).

![](pmed.1001376.t002){#pmed-1001376-t002-2}

  Paper                                               Country of Study                                      Data Source (s)                                                           Population Included                         Years of Diagnosis           Measure of SEP           No of SEP Groups   Treatment Given Within   Age Range   Confounders Controlled For:   Reason for Exclusion   Quality score                                                                                                                                                                                                                                                                      
  -------------------------------------------------- ------------------ --------------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------- -------------------------------- ------------------ ------------------------ ----------- ----------------------------- ---------------------- --------------- ----- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ---
  Battersby et al, 2004 [@pmed.1001376-Battersby1]        England                            HES and East Anglian Cancer Intelligence Unit                       17 PCTs in Norfolk, Suffolk and Cambridgeshire with HES record       1997--2000       IMD (weighted average for PCT)          NR                    NR                NR                   Yes                       Yes                 No         Yes                                                                                          Incidence                                                                                                     Rate correlated against deprivation, by sex              1
  Bendzsak et al, 2011 [@pmed.1001376-Bendzsak1]           Canada        Ontario Cancer Registry linked to CIHI hospital data, Insurance data and RPD database                              Ontario                                   2003--2004            Neighbourhood income               5                 12 months           20--75+                Yes                       Yes                 No         No                                                                                     Univariable analysis                                                                                                             Univariable rate                            2
  Cartman et al, 2002 [@pmed.1001376-Cartman1]            England               Northern and Yorkshire Cancer Registry and Information Service (NYCRIS)                                 Yorkshire region                              1986--1994                     NR                        NR                    NR             \<65--75+               Yes                       Yes                 No         Yes                                                                                    Univariable analysis                                                                                                             Univariable rate                            1
  Hui et al, 2005 [@pmed.1001376-Hui1]                   Australia                         NSW Central Cancer Registry and hospital records                                  Residents of two area Health Services                       1996                    SEIFA-IRSD                    5                     NR             \<50--70+               Yes                       Yes                 Yes        Yes                                                                                    Univariable analysis                                                                                                             Univariable rate                            2
  Madelaine et al, 2002 [@pmed.1001376-Madelaine1]         France                                     Manche Dept Cancer Registry                                                            Manche                                   1997--1999                   INSEE                       4                     NR             \<54--75+               Yes                       Yes                 Yes        Yes                                                                                         Urban/rural                                                                                         Unemployed used as low SEP group and SEP group 2 used as baseline   2
  Pagano et al, 2010 [@pmed.1001376-Pagano1]               Italy                                   Piedmont Cancer Registry of Turin                                                         Turin                                    2000--2003              Education level                  3                 12 months          \<65--75+               Yes                       Yes                 Yes        Yes                                                                                       Marital status                                                                                               Different comparator -- *other* not *no* treatment           2
  Patel et al, 2007 [@pmed.1001376-Patel1]                England                                       Thames Cancer Registry                                                         Southeast England                              1994--2003                    IMD                        5                  6 months           0--100                 Yes                       Yes                 Yes        Yes                                                                              Cancer network, year of diagnosis                                                                                   Adjusted rates with no CIs. Possible errors in numbers.        2
  Stevens et al, 2009 [@pmed.1001376-Stevens3]          New Zealand       Regional hospital and oncology databases checked against NZ cancer Registry listing     Auckland-Northland region patients managed in secondary care           2004               NZ Deprivation Index               10                    NR             \<60--80+               Yes                       Yes                 Yes        Yes                                                                                    Univariable analysis                                                                                            Univariable OR. Multivariable SEP results not shown          2
  Younis et al, 2008 [@pmed.1001376-Younis1]               Canada                            Nova Scotia cancer registry and chart review                                                 Nova Scotia                                    2005             Median household income              2                     NR              65--75+                Yes                       Yes                 Yes        Yes   Co-morbidity, performance status, hospital, surgery type, post-op complications, surgeon, medical oncology, education level, distance to cancer centre, marital status, smoking history      Univariable rate. Multivariable OR only for referral by SEP      2

Quality scores range from 1 (lowest quality) to 6 (highest quality).

CI, confidence interval; HES, Hospital Episode Statistics; IMD, Index of Multiple Deprivation; NR, not reported; NSW, New South Wales; OR, odds ratio; PCT, Primary Care Trust; SEIA-IRSD, Socioeconomic Indexes for Areas - Index of Relative Social Disadvantage; SEP, socioeconomic position; UHCS, universal health care system.

Eighteen papers were from non-UHCSs, all of which were from the USA ([Tables 3](#pmed-1001376-t003){ref-type="table"} and [4](#pmed-1001376-t004){ref-type="table"}). The majority of non-UHCS papers used sub-groups of the National Cancer Institute\'s Surveillance, Epidemiology and End Results (SEER) database population and, again, some population overlap was found.

10.1371/journal.pmed.1001376.t003

###### Characteristics of included studies potentially suitable for meta-analysis (non-universal health care systems).

![](pmed.1001376.t003){#pmed-1001376-t003-3}

  Paper                                               Country of Study                                       Data Source (s)                                                           Population Included                        Years of Diagnosis                            Measure of SEP                                          No of SEP Groups                 Treatment Given Within   Age Range   Confounders Controlled For:   Quality Score                                                                                                                                                                  
  -------------------------------------------------- ------------------ ----------------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------- ------------------------------------------------------------------- --------------------------------------------- ------------------------ ----------- ----------------------------- --------------- ----- ----- --------------------------------------------------------------------------------------------------------------------------------------------------- ---
  Bradley et al, 2008 [@pmed.1001376-Bradley1]              USA                     Michigan Cancer Registry and Michigan Medicare and Medicaid data                   Medicare and Medicare/Medicaid patients in Michigan            1997--2000               Census tract median household income (high v low)                                2                               6 months           66--80+                Yes                    Yes        Yes   Yes                                                 Co-morbidity, insurance type, ethnicity, urban/rural                                                  4
  Davidoff et al, 2010 [@pmed.1001376-Davidoff1]            USA                               SEER cancer registry linked to Medicare data                                  Medicare patients from 16 SEER registries                 1997--2002                     Census tract median household income                                       4                               90 days            66--85+                Yes                    Yes        Yes   Yes                        Co-morbidity, performance status, ethnicity, marital status, rural/urban, prior Medicaid, tumour grade                         5
  Earle et al, 2000 [@pmed.1001376-Earle1]                  USA                               SEER cancer registry linked to Medicare data                                  Medicare patients from 11 SEER registries                 1991--1993       Census tract median household income(increase in OR per quintile)                        5                               4 months           65--104                Yes                    Yes        Yes   Yes                                 Co-morbidity, year of diagnosis, ethnicity, rural/urban, teaching hospital, SEER area                                 5
  Esnoala et al, 2008 [@pmed.1001376-Esnaola1]              USA          South Carolina central cancer Registry linked to inpatient and outpatient surgery files                          South Carolina                              1996--2002            Income, zip code level (poverty/not living in poverty)                              2                                  NR             \<50--80+               Yes                    Yes        Yes   Yes                  Co-morbidity, year of diagnosis, insurance type, ethnicity, rural/urban, education, marital status, tumour location                  4
  Greenwald et al, 1998 [@pmed.1001376-Greenwald1]          USA                                           SEER cancer registry                                     3 (Detroit, San Francisco, Seattle) out of 9 SEER registries       1978--1982       Census tract median household income (increase in OR per decile)                        10                                  NR              \< = 75                Yes                    Yes        Yes   Yes                                                             Performance status, ethnicity                                                             6
  Hardy et al, 2009 [@pmed.1001376-Hardy1]                  USA                               SEER cancer registry linked to Medicare data                                  Medicare patients from 17 SEER registries                 1991--2002            \% individuals below poverty line at census tract level                             4                                  NR              65--85+                Yes                    Yes        Yes   Yes                                Co-morbidity, year of diagnosis, ethnicity, marital status, SEER area, other treatment                                 5
  Hayman et al, 2007 [@pmed.1001376-Hayman1]                USA                               SEER cancer registry linked to Medicare data                                  Medicare patients from 11 SEER registries                 1991--1996                     Census tract median household income                                       5                           4 months/2 years       65--85+                Yes                    Yes        Yes   Yes   Co-morbidity, year of diagnosis, ethnicity, SEER area, hospitalisation, teaching hospital, distance to nearest RT centre, receipt of chemotherapy   5
  Lathan et al, 2008 [@pmed.1001376-Lathan1]                USA                               SEER cancer registry linked to Medicare data                                  Medicare patients from 11 SEER registries                 1991--1999         Census tract median household income (inc in OR per quintile)                          5                                  NR                65+                  Yes                    Yes        Yes   Yes                  Co-morbidity, ethnicity, SEER registry, urban, non-profit hospital, patient volume, % of black patients in hospital                  5
  Polednak, 2001 [@pmed.1001376-Polednak1]                  USA             Connecticut Tumor Registry (SEER) and inpatient hospital discharge database (HDD)                              Connecticut                                1992--1997                           Census tract poverty rate                                            5                                  NR             \<55--80+               Yes                    Yes        Yes   No                                                         Co-morbidity, ethnicity, marital status                                                        4
  Smith et al, 1995 [@pmed.1001376-Smith1]                  USA                           Virginia Cancer Registry and Medicare claims database                          Medicare patients from Virginia cancer registry              1985--1989             Census tract: median household income by race and age         Contin-uous[a](#nt110){ref-type="table-fn"}          6 months           65--85+                Yes                    Yes        Yes   Yes                                         Co-morbidity, ethnicity, county of residence, distance to oncologist                                          5

Quality scores range from 1 (lowest quality) to 6 (highest quality).

Odds ratio for increase per \$10,000 income.

CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; SEER, National Cancer Institute\'s Surveillance, Epidemiology and End Results database; SEP, socioeconomic position.

10.1371/journal.pmed.1001376.t004

###### Characteristics of included studies not suitable for meta-analysis (non-universal health care systems).

![](pmed.1001376.t004){#pmed-1001376-t004-4}

  Paper                                               Country                                Data Source (s)                                                 Population Included                    Years of Diagnosis                                         Measure of SEP                                                       No of SEP Groups                 Treatment Given Within   Age Range   Confounders Controlled For:   Reasons for Exclusion   Quality Score                                                                                                                                                                                                                                         
  -------------------------------------------------- --------- ---------------------------------------------------------------------------- ------------------------------------------------------ -------------------- --------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------ ----------- ----------------------------- ----------------------- --------------- ----- -------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ---
  Bach et al, 1999 [@pmed.1001376-Bach1]                USA                    SEER cancer registry linked to Medicare data                       Medicare patients from 10 SEER registries             1985--1993             Median income in zip code of residence (lowest quartile compared to highest 3)                               2                                  NR              65--75+                Yes                        Yes                 Yes        Yes                                                    Co-morbidity, ethnicity, SEER area                                                            OR of surgery for black v white, univariable rates of surgery used here           2
  Earle et al, 2002 [@pmed.1001376-Earle2]              USA                    SEER cancer registry linked to Medicare data                       Medicare patients from 11 SEER registries             1991--1996                                  Census tract median household income                                                    5                               any time             NR                   Yes                        Yes                 Yes        Yes                       Co-morbidity, ethnicity, year of diagnosis, teaching hospital, seen by oncologist, SEER area                               SEP non sig in multivariable analysis but only univariable rate shown.            2
  Lathan et al, 2006 [@pmed.1001376-Lathan2]            USA                    SEER cancer registry linked to Medicare data                       Medicare patients from 11 SEER registries             1991--1999                                  Census tract median household income                                                    5                                  NR                65+                  Yes                        Yes                 Yes        Yes                                   Co-morbidity, ethnicity, SEER region, teaching hospital, rural/urban                                                                       Quality issues                                        2
  Ou et al, 2008 [@pmed.1001376-Ou1]                    USA                     California Cancer Registry (part of SEER)                                         California                            1989--2003                  Composite measure (7 indicators of education, income and occupation)                                    5                                  NR               0--89                 Yes                        Yes                 Yes        Yes                                Ethnicity, tumour grade, tumour location, histologic grade, marital status                                          SEP not reported in multivariable analysis. Univariable rate shown.             2
  Suga et al, 2010 [@pmed.1001376-Suga1]                USA                             California Cancer Registry                                 Sacramento region in Northern California             1994--2004       Census tract composite variable income, education, employment, poverty, rent, housing value                        5                                  NR                NR                   Yes                        Yes                 Yes        Yes                                                    Ethnicity, residence (urban/rural)                                                                                            No CIs                                            2
  Tammemagi et al, 2004 [@pmed.1001376-Tammemagi1]      USA                    Josephine Ford Cancer Center Tumor Registry                   Detroit (receiving care at Henry Ford Health System)       1995--1998                                  Census tract median household income                               Contin-uous[a](#nt113){ref-type="table-fn"}             NR                NR                   Yes                        Yes                 Yes        Yes                             Co-morbidity, ethnicity, marital status, smoking history, alcohol use, drug use                                         SEP not reported in multivariable analysis. Univariable OR shown.              2
  Wang et al, 2008 [@pmed.1001376-Wang1]                USA                    SEER cancer registry linked to Medicare data                          Medicare patients 11 SEER registries               1992--2002                                   \% below census tract poverty level                                                    4                               4 months           66--85                 Yes                        Yes                 Yes        Yes   Co-morbidity, ethnicity, year of diagnosis, grade, SEER region, census tract education, marital status, teaching hospital, radiation   SEP not reported in multivariable analysis.OR for consultation but not treatment shown.   1
  Yang et al, 2010 [@pmed.1001376-Yang1]                USA     Florida Cancer registry linked to inpatient and outpatient medical records                         Florida                              1998--2002                                       Census tract poverty level                                                         4                                  NR             \<45--70+               Yes                        Yes                 Yes        Yes                                                        Univariable analysis only                                                                                            Univariable rate                                       2

Quality scores range from 1 (lowest quality) to 6 (highest quality).

Odds ratio for increase per \$10,000 income.

CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; SEER, National Cancer Institute\'s Surveillance, Epidemiology and End Results database; SEP, socioeconomic position.

An individual measure of SEP (education level) was used in one study [@pmed.1001376-Berglund1]. All other studies used area-level measures of deprivation, income, poverty, or education level.

In terms of quality, the non-UHCS studies that carried out multivariable analyses had better control for confounding than did UHCS studies, as they tended to stratify by stage and histology. However, half of the non-UHCS papers used a Medicare-only population aged over 65, and so were more restrictive in population terms than the UHCS studies.

Twenty-nine papers met the criteria for meta-analysis---19 from UHCSs and 10 from non-UHCSs. However, six studies that examined receipt of treatment in low compared to high SEP presented the results as a single OR and so could not be included in the meta-analyses. Seventeen studies were included in the final meta-analyses and a further six in the sensitivity meta-analyses.

Surgery {#s3b}
-------

Thirty-one papers (29 study populations) included receipt of surgery as an outcome---18 UHCS papers (15 study populations) and 13 non-UHCS papers (14 study populations) ([Tables 5](#pmed-1001376-t005){ref-type="table"} and [6](#pmed-1001376-t006){ref-type="table"}). Of the papers that reported measures of significance (CIs or p-values), 20 out of 27 (74%) reported that lower SEP was significantly associated with lower likelihood of surgery when comparing the lowest with the highest SEP group, although three of these 20 papers did not find a significant trend across groups.

10.1371/journal.pmed.1001376.t005

###### Likelihood of receipt of surgery by SEP group (universal health care systems).

![](pmed.1001376.t005){#pmed-1001376-t005-5}

  Study                                               No. Receiving Surgery   Cohort No./No. Eligible   Rate    Histology   OR/Rate in Q1 (95% CI)   OR/Rate in Q2 (95% CI)   OR/Rate in Q3 (95% CI)   OR/Rate in Q4 (95% CI)   OR/rate in Q5 (95% CI)          p-Value           Quality Score   Meta-Analysis                                 Further Information
  -------------------------------------------------- ----------------------- ------------------------- ------- ----------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ --------------- --------------- ----------------------------------------------------------------------------------
  Bendzsak et al, 2011 [@pmed.1001376-Bendzsak1]              1220                     6499             18.77      any               21.1                     18.3                     19.7                     18.8                     16.8                     0.02                  2               N                                         Univariable rate
  Campbell et al, 2002 [@pmed.1001376-Campbell1]               85                       653             13.02      any               1.00             0.76 (0.28 to 2.09)      0.70 (0.27 to 1.84)      0.88 (0.35 to 2.22)      0.59 (0.23 to 1.53)             0.423                  5               Y                                           P for trend
  Hui et al, 2005 [@pmed.1001376-Hui1]                         NR                       526                        any                29                       28                       20                       27                       20                      0.19                  2               N                                         Univariable rate
  Jack et al, 2003 [@pmed.1001376-Jack1]                       NR                      32818                       any                                                                                                           0.98 (0.95 to 1.01)             0.7759                 4               N        
  Jack et al, 2006 [@pmed.1001376-Jack2]                       42                       695             6.04       any               1.00             0.82 (0.33 to 2.07)      0.89 (0.35 to 2.25)      0.16 (0.03 to 0.73)      0.75 (0.27 to 2.09)             0.1326                 6               Y                           Subset of Jack et al (2003) pop, p for trend
  Jones et al,2008 [@pmed.1001376-Jones1]                     3552                     34923            10.17      any                                                                                                           0.99 (0.99 to 1.00)             \<0.01                 4               N        
  Pollock &Vickers, 1998 [@pmed.1001376-Pollock1]             2869                     38668            7.42       any               1.00             0.83 (0.69 to 1.00)      0.73 (0.61 to 0.88)      0.82 (0.68 to 0.98)      0.58 (0.48 to 0.70)             \<0.05                 3               Y                                 Hospital population, p for trend
  Raine et al, 2010 [@pmed.1001376-Raine1]                    8790                     36902            23.82      any       1.63 (1.49 to 1.77)      1.58 (1.46 to 1.72)      1.45 (1.35 to 1.57)      1.34 (1.25 to 1.45)              1.00                   \<0.001                 3               Y                                  Elective admission population
  Raine et al, 2010 [@pmed.1001376-Raine1]                    8923                    186741            4.78       any               5.5                      5.2                      4.8                      4.4                      4.5                       NR                   2               N                                 All admissions, univariable rate
  Battersby et al, 2004 [@pmed.1001376-Battersby1]             387                     4092             9.46      NSCLC                                                                                                         −0.10 (−0.55 to 0.40)              NR                   1               N         Rate by sex correlated with deprivation score (men), with overall treatment rate
  Battersby et al, 2004 [@pmed.1001376-Battersby1]                                                                NSCLC                                                                                                         −0.16 (−0.59 to 0.35)              NR                   1               N                      Rate by sex correlated with deprivation score (women)
  Berglund et al, 2010 [@pmed.1001376-Berglund1]               626                     3369             18.58     NSCLC      1.93 (1.25 to 3.00)                               1.33 (0.98 to 1.81)                                       1.00                      NR                   6               Y        
  Berglund et al, 2010 [@pmed.1001376-Berglund1]               534                      932             57.30     NSCLC      2.84 (1.40 to 5.79)                               1.53 (1.01 to 2.31)                                       1.00                      NR                   6             Y(S)                                Early stage only - stage IA-IIB
  Berglund et al, 2012 [@pmed.1001376-Berglund2]               899                     1826             49.18     NSCLC              1.00             0.74 (0.51 to 1.06)      0.71 (0.49 to 1.02)      0.73 (0.52 to 1.03)      0.67 (0.48 to 0.95)              0.29                  6               Y                          Early stage only -- stage IA-IIB, p for trend
  Cartman et al, 2002 [@pmed.1001376-Cartman1]                2401                     12570            19.10     NSCLC              19.1                                                                                                18.6                      NR                   1               N                                         Univariable rate
  Crawford et al, 2009 [@pmed.1001376-Crawford1]              3335                     18324            18.20     NSCLC              1.00             0.90 (0.81 to 1.00)                               0.82 (0.74 to 0.91)      0.80 (0.72 to 0.89)     \<0.05, \<0.01, \<0.01         4               Y                                   Individual P values reported
  Mahmud et al, 2003 [@pmed.1001376-Mahmud1]                   866                     4451             19.46     NSCLC              19.8                                              18.0                                              21.0                      NR                   2               N                                         Univariable rate
  McMahon et al, 2011 [@pmed.1001376-McMahon1]                2374                     18813            12.62     NSCLC              1.00             0.95 (0.83 to 1.09)      0.95 (0.83 to 1.08)      0.90 (0.79 to 1.03)      0.78 (0.65 to 0.94)             0.018                  4               Y                                           P for trend
                                                                                                                                                                                                                                 0.96 (0.93 to 0.99)             0.018                                  N                            Paper presents results in 2 different ways
  Riaz et al, 2012 [@pmed.1001376-Riaz1]                      6900                     77349            8.92      NSCLC              1.00             0.88 (0.80 to 0.96)      0.91 (0.83 to 0.99)      0.82 (0.76 to 0.89)      0.76 (0.70 to 0.83)             \<0.01                 4             Y(S)                                          P for trend
  Rich et al, 2011(1) [@pmed.1001376-Rich2]                   3427                     24175            14.18     NSCLC              1.00             1.13 (0.98 to 1.32)      1.18 (1.02 to 1.37)      1.01 (0.87 to 1.16)      1.11 (0.96 to 1.27)              0.77                  5             Y(S)                         Subset of Rich et al 2011 (2) pop, p for trend
  Rich et al, 2011(2) [@pmed.1001376-Rich1]                   4481                     34436            13.01     NSCLC              1.00             0.99 (0.88 to 1.11)      1.04 (0.92 to 1.19)      0.98 (0.84 to 1.13)      0.86 (0.71 to 1.04)             0.132                  5             Y(S)                                          P for trend

Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in [Tables 1](#pmed-1001376-t001){ref-type="table"}--[4](#pmed-1001376-t004){ref-type="table"} in the column entitled "No. of SEP groups." Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position, Q5, low socioeconomic position.

CI, confidence interval; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position; UHCS, universal health care system.

10.1371/journal.pmed.1001376.t006

###### Likelihood of receipt of surgery by SEP group (non-universal health care systems).

![](pmed.1001376.t006){#pmed-1001376-t006-6}

  Study                                               No. Receiving Surgery   Cohort No./No. Eligible   Rate    Stage(s) Included   Histology   OR/Rate in Q1 (95% CI)   OR/Rate in Q2 (95% CI)   OR/Rate in Q3 (95% CI)   OR/Rate in Q4 (95% CI)   OR/Rate in Q5 (95% CI)              p-Value               Quality Score   Meta-Analysis                                  Further Information
  -------------------------------------------------- ----------------------- ------------------------- ------- ------------------- ----------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ -------------------------------- --------------- --------------- ------------------------------------------------------------------------------------
  Bradley et al, 2008 [@pmed.1001376-Bradley1]                1336                     2626             50.88       I,II,IIIa         NSCLC              1.00                                                                                        0.80 (0.67 to 0.98)                 \<0.05                     4               Y        
  Esnoala et al, 2008 [@pmed.1001376-Esnaola1]                 NR                      2791                           local           NSCLC              1.00                                                                                        0.67 (0.51 to 0.88)                 0.005                      4               Y        
  Greenwald et al, 1998 [@pmed.1001376-Greenwald1]            3053                     5157             59.20           I             NSCLC                                                                                                                 1.076                       \<0.0001                    6               N                                     SE = 0.011 (no CIs shown)
  Hardy et al, 2009 [@pmed.1001376-Hardy1]                    11834                    19658            60.20         I,II            NSCLC              1.00             0.92 (0.84 to 1.14)                               0.78 (0.75 to 1.03)      0.68 (0.60 to 0.77)         \>0.05, \>0.05, \<0.05             5               Y         Individual p values reported corrected OR supplied[a](#nt118){ref-type="table-fn"}
  Lathan et al, 2008 [@pmed.1001376-Lathan1]                  4563                     9688             47.10       I,II,III          NSCLC                                                                                                          1.06 (1.02 to 1.11)                   NR                       5               N                                 Subset of Lathan et al (2006) pop
  Ou et al, 2008 [@pmed.1001376-Ou1]                          16185                    19700            82.16           I             NSCLC              86.9                     84.8                     81.1                     79.6                     74.5                       \<0.001                     2               N        
  Smith et al, 1995 [@pmed.1001376-Smith1]                     801                     2813             28.47         local           NSCLC                                                                                                          1.04 (0.90 to 1.19)                \>0.001                     5               N        
  Tammemagi et al, 2004 [@pmed.1001376-Tammemagi1]             NR                      1155                           I,II            NSCLC                                                                                                          1.19 (1.03 to 1.30)                  0.02                      2               N                                           Univariable OR
  Bach et al, 1999 [@pmed.1001376-Bach1]                       550                      860             63.95         I,II            NSCLC              67.5                                                                                                61.9                          NR                       2               N                                          Surgery (blacks)
  Bach et al, 1999 [@pmed.1001376-Bach1]                      7763                     10124            76.68         I,II            NSCLC              78.0                                                                                                70.7                          NR                       2               N                                          Surgery (whites)
  Polednak, 2001 [@pmed.1001376-Polednak1]                    1385                     1564             88.55         I,II            NSCLC              1.00             1.27 (0.74 to 2.18)      1.15 (0.65 to 2.03)      1.17 (0.67 to 2.04)      1.78 (1.05 to 3.01)     \>0.05, \>0.05, \>0.05, \<0.05         4               Y                    Odds of not receiving surgery, individual p values reported
  Smith et al, 1995 [@pmed.1001376-Smith1]                     57                      2396             2.38         distant          NSCLC                                                                                                          1.27 (0.97 to 1.67)                \>0.001                     5               N        
  Suga et al, 2010 [@pmed.1001376-Suga1]                       NR                      12395                                          NSCLC                                                                                                                  1.17                       \<0.001                     2               N                               Surgery after invasive staging, no CIs
  Suga et al, 2010 [@pmed.1001376-Suga1]                       NR                      12395                                          NSCLC                                                                                                                  1.18                       \<0.001                     2               N                             Surgery after non-invasive staging, no CIs
  Lathan et al, 2006 [@pmed.1001376-Lathan2]                   NR                      14224                                          NSCLC                                                                                                          1.05 (1.02 to 1.08)                   NR                       2               N        
  Yang et al, 2010 [@pmed.1001376-Yang1]                       NR                       NR                             all             all               24.6                     22.2                                              20.7                     18.3                        \<0.01                     2               N                                        Univariable analysis

Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in [Tables 1](#pmed-1001376-t001){ref-type="table"}--[4](#pmed-1001376-t004){ref-type="table"} in the column entitled "No. of SEP groups." Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.

We are grateful to the authors for supplying a corrected OR to allow inclusion of this study in the meta-analysis.

CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; pop, population; SE, standard error; SEP, socioeconomic position.

Meta-analysis of all 16 populations that were suitable for inclusion showed a significant negative effect of lower SEP on the likelihood of receiving surgery: OR = 0.72 (95% CI 0.65 to 0.80), p\<0.001, I^2^ = 80% ([Figure S1](#pmed.1001376.s001){ref-type="supplementary-material"}). Including only non-overlapping study populations (n = 12) gave a similar result: OR = 0.68 (95% CI 0.63 to 0.75), p\<0.001, I^2^ = 53% ([Figure 2](#pmed-1001376-g002){ref-type="fig"}). Similar results were also seen for the subgroup of eight papers including NSCLC patients only (OR = 0.73 \[95% CI 0.68 to 0.80\] p\<0.001, I^2^ = 24%) ([Figure S2](#pmed.1001376.s002){ref-type="supplementary-material"}) and with further stratification by health care system; NSCLC (UHCS): OR = 0.75 (95% CI 0.66 to 0.85), p\<0.001, I^2^ = 29%; NSCLC (non-UHCS, early stage only, co-morbidity included): OR = 0.71 (95% CI 0.64 to 0.78) p\<0.001; I^2^ = 2% ([Figure 2](#pmed-1001376-g002){ref-type="fig"}).

![Meta-analysis of odds of receipt of surgery in low versus high SEP.\
CI, confidence interval; non-UHCS, non-universal health care system; NSCLC, non-small cell lung cancer; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.](pmed.1001376.g002){#pmed-1001376-g002}

Lower SEP was associated with a lower likelihood of receiving lung cancer surgery, in both types of health care system, and in studies where histology and stage at diagnosis were taken into account.

Chemotherapy {#s3c}
------------

Twenty-three papers included chemotherapy as an outcome---14 UHCS papers (12 populations) and nine non-UHCS papers (10 populations) ([Tables 7](#pmed-1001376-t007){ref-type="table"} and [8](#pmed-1001376-t008){ref-type="table"}). Of the 21 papers that reported measures of significance, 15 (71%) reported that lower SEP was significantly associated with lower likelihood of receipt of chemotherapy.

10.1371/journal.pmed.1001376.t007

###### Likelihood of receipt of chemotherapy by SEP group (universal health care systems).

![](pmed.1001376.t007){#pmed-1001376-t007-7}

  Study                                             No. Receiving Chemo   Cohort No./No. Eligible   Rate    Histology   OR/Rate in Q1 (95% CI)   OR/Rate in Q2 (95% CI)   OR/Rate in Q3 (95% CI)   OR/Rate in Q4 (95% CI)   OR/Rate in Q5 (95% CI)   p-Value   Quality Score   Meta-Analysis                           Further Information
  ------------------------------------------------ --------------------- ------------------------- ------- ----------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ --------- --------------- --------------- ---------------------------------------------------------------------
  Berglund et al, 2012 [@pmed.1001376-Berglund2]           3661                    10039            36.47      any               1.00             0.90 (0.77 to 1.06)      0.78 (0.67 to 0.91)      0.77 (0.66 to 0.89)      0.75 (0.65 to 0.87)     \<0.01          6               Y                  NSCLC stage IIIA-IV & all stage SCLC, p for trend
  Campbell et al, 2002 [@pmed.1001376-Campbell1]            124                     653             18.99      any               1.00             0.58 (0.21 to 1.57)      0.72 (0.29 to 1.78)      0.41 (0.16 to 1.05)      0.39 (0.16 to 0.96)      0.028          5               Y        
  Jack et al, 2003 [@pmed.1001376-Jack1]                    NR                     32818                       any                                                                                                           0.96 (0.94 to 0.98)     0.0001          4               N                          Subset of Patel et al (2007) pop
  Jack et al, 2006 [@pmed.1001376-Jack2]                    108                     695             15.54      any               1.00             1.04 (0.50 to 2.16)      0.81 (0.38 to 1.70)      0.89 (0.43 to 1.85)      1.04 (0.48 to 2.25)     0.9130          6               Y                    Subset of Patel et al (2007) pop, p for trend
  Jones et al,2008 [@pmed.1001376-Jones1]                  5783                    34923            16.56      any                                                                                                           0.99 (0.99 to 0.99)     \<0.01          4               N        
  Patel et al, 2007 [@pmed.1001376-Patel1]                 11217                   67312            16.66      any               18.3                     15.7                     14.5                     12.8                     12.8            \<0.001         2               N                               Adjusted rates, no CIs
  Rich et al, 2011(1) [@pmed.1001376-Rich2]                14168                   59592            23.78      any               1.00             0.97 (0.90 to 1.04)      0.89 (0.83 to 0.96)      0.83 (0.77 to 0.89)      0.85 (0.79 to 0.91)     \<0.01          5             Y(S)       
  Hui et al, 2005 [@pmed.1001376-Hui1]                      NR                      526                        any                31                       34                       36                       27                       26              0.15           2               N                                  Univariable rate
  Berglund et al, 2010 [@pmed.1001376-Berglund1]           1285                    3369             38.14     NSCLC      1.35 (1.00 to 1.81)                               1.25 (1.03 to 1.52)                                       1.00              NR            6               Y        
  Pagano et al, 2010 [@pmed.1001376-Pagano1]                430                    1231             34.93     NSCLC              1.00                                      0.98 (0.64 to 1.50)                               1.63 (1.08 to 2.44)       NR            2               N               Odds of receiving chemo +/or radio rather than surgery
  Younis et al, 2008 [@pmed.1001376-Younis1]                29                      108             26.85     NSCLC       4.7 (1.3 to 17.8)                                                                                          1.0              0.015          2               N         Odds of referral for adjuvant chemo after surgery, stage I, II, III
  Cartman et al, 2002 [@pmed.1001376-Cartman1]             1349                    2448             55.11     SCLC               52.1                                                                                                56.8              NR            1               N                                  Univariable rate
  Crawford et al, 2009 [@pmed.1001376-Crawford1]           3619                    5510             65.68     SCLC               1.00             1.10 (0.94 to 1.30)                               0.91 (0.78 to 1.08)      0.94 (0.80 to 1.11)     \>0.05          4               Y                     Individual p-values, all reported as \>0.05
  Mahmud et al, 2003 [@pmed.1001376-Mahmud1]                425                    1002             42.42     SCLC               37.8                                              40.5                                              50.2              NR            2               N                                  Univariable rate

Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in [Tables 1](#pmed-1001376-t001){ref-type="table"}--[4](#pmed-1001376-t004){ref-type="table"} in the column entitled "No. of SEP groups." Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.

CI, confidence interval; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position; UHCS, universal health care system.

10.1371/journal.pmed.1001376.t008

###### Likelihood of receipt of chemotherapy by SEP group (non-universal health care systems).

![](pmed.1001376.t008){#pmed-1001376-t008-8}

  Study                                               No. Receiving Chemo   Cohort No./No. Eligible   Rate      Stage      Histology   OR/Rate in Q1 (95% CI)   OR/Rate in Q2 (95% CI)   OR/Rate in Q3 (95% CI)   OR/Rate in Q4 (95% CI)   OR/Rate in Q5 (95% CI)          p-Value           Quality Score   Meta-Analysis                                            Further Information
  -------------------------------------------------- --------------------- ------------------------- ------- ------------ ----------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ --------------- --------------- -------------------------------------------------------------------------------------------------------
  Bradley et al, 2008 [@pmed.1001376-Bradley1]                643                    2348             27.39   I,II, IIIa     NSCLC              1.00                                                                                        1.09 (0.87 to 1.37)             \>0.05                 4               Y        
  Hardy et al, 2009 [@pmed.1001376-Hardy1]                   2951                    19658            15.01     I, II        NSCLC              1.00             0.91 (0.81 to 1.02)                               0.96 (0.85 to 1.09)      0.85 (0.74 to 0.98)     \>0.05, \>0.05, \<0.05         5               Y                                             Individual p-values reported
  Ou et al, 2008 [@pmed.1001376-Ou1]                         1175                    19700            5.96        I          NSCLC              5.3                      5.7                      5.3                      6.9                      7.4                     0.001                  2               N                                                 Univariable analysis
  Davidoff et al, 2010 [@pmed.1001376-Davidoff1]             5499                    21285            25.84    IIIB, IV      NSCLC      1.43 (1.28 to 1.60)      1.17 (1.05 to 1.30)                               1.11 (1.00 to 1.22)              1.00            \<0.01, \<0.01, \<0.05         5               Y                                             Individual p-values reported
  Earle et al, 2000 [@pmed.1001376-Earle1]                   1356                    6308             21.50       IV         NSCLC                                                                                                          1.07 (1.02 to 1.12)             0.0077                 5               N                                                Subset of Earle (2002)
  Earle et al, 2002 [@pmed.1001376-Earle2]                   8813                    12015            73.35       IV         NSCLC               41                       41                       36                       31                       27                     \>0.05                 2               N         Univariable analysis only. SEP was included in multivariable analysis but non-sig (figs not reported)
  Hardy et al, 2009 [@pmed.1001376-Hardy1]                   26417                   51243            51.55    III, IV       NSCLC              1.00             0.87 (0.78 to 0.96)                               0.76 (0.63 to 0.90)      0.60 (0.45 to 0.79)     \<0.05, \<0.05, \<0.05         5             Y(S)                                            Individual p-values reported
  Tammemagi et al, 2004 [@pmed.1001376-Tammemagi1]            NR                     1155                       III,IV       NSCLC                                                                                                          1.09 (1.01 to 1.18)              0.03                  2               N                                                    Univariable OR
  Davidoff et al, 2010 [@pmed.1001376-Davidoff1]              749                    1946             38.49    IIIB, IV      NSCLC       0.86(0.69 to 1.08)      0.96 (0.77 to 1.19)                               0.99 (0.81 to 1.22)              1.00                      NR                   5               N                                   Odds of single agent compared to two-agent chemo.
  Wang et al, 2008 [@pmed.1001376-Wang1]                     1521                    3196             47.59    II, IIIa      NSCLC              1.00             1.08 (0.97 to 1.21)                               1.08 (0.97 to 1.21)      0.97 (0.85 to 1.10)               NR                   1               N                                       Odds of receiving oncology consultation.
  Yang et al, 2010 [@pmed.1001376-Yang1]                      NR                      NR                         All          any               32.2                     30.7                                              29.9                     30.1                    \<0.01                 2               N                                                 Univariable analysis

Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in [Tables 1](#pmed-1001376-t001){ref-type="table"}--[4](#pmed-1001376-t004){ref-type="table"} in the column entitled "No. of SEP groups." Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.

CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position.

Meta-analysis of the ten populations that were suitable for inclusion found a significant negative effect of lower SEP on the likelihood of receiving chemotherapy: OR = 0.81 (95% CI 0.73 to 0.89), p\<0.001, I^2^ = 68% ([Figure S3](#pmed.1001376.s003){ref-type="supplementary-material"}). Similarly, in a meta-analysis of the eight papers containing non-overlapping populations that were selected for inclusion, the odds of receiving chemotherapy were significantly lower for those with low SEP compared to those with high SEP (OR = 0.82 \[95% CI 0.72 to 0.93\], p = 0.003, I^2^ = 67%), overall. A similar pattern was found in UHCS (OR = 0.80 \[95% CI 0.68 to 0.95\], p = 0.01, I^2^ = 46%); and in non-UHCS settings (OR = 0.85 \[95% CI 0.68 to 1.07\], p = 0.16, I^2^ = 85%), although this did not reach significance ([Figure 3](#pmed-1001376-g003){ref-type="fig"}).

![Meta-analysis of odds of receipt of chemotherapy in low versus high SEP.\
CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.](pmed.1001376.g003){#pmed-1001376-g003}

Radiotherapy {#s3d}
------------

Eighteen papers (18 populations) examined receipt of radiotherapy for lung cancer---12 in UHCS settings (11 populations) and six in non-UHCS settings (seven populations) ([Tables 9](#pmed-1001376-t009){ref-type="table"} and [10](#pmed-1001376-t010){ref-type="table"}). Only one UHCS study found an association between SEP and receipt of radiotherapy. The non-UHCS studies had very heterogeneous outcomes.

10.1371/journal.pmed.1001376.t009

###### Likelihood of receipt of radiotherapy by SEP group (universal health care systems).

![](pmed.1001376.t009){#pmed-1001376-t009-9}

  Study                                             No. Receiving Radio   Cohort No./No. Eligible   Rate      Histology     OR/Rate in Q1 (95% CI)   OR/Rate in Q2 (95% CI)   OR/Rate in Q3 (95% CI)   OR/Rate in Q4 (95% CI)   OR/Rate in Q5 (95% CI)   p-Value   Quality Score   Meta-Analysis               Further Information
  ------------------------------------------------ --------------------- ------------------------- ------- --------------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ --------- --------------- --------------- ----------------------------------------------
  Berglund et al, 2012 [@pmed.1001376-Berglund2]           1054                    2771             38.04        any                 1.00             1.16 (0.88 to 1.54)      1.17 (0.90 to 1.53)      1.18 (0.91 to 1.53)      0.99 (0.77 to 1.29)      0.67           6               Y                 Stage III only, p for trend
  Campbell et al, 2002 [@pmed.1001376-Campbell1]            412                     653             63.09        any                 1,00             2.08 (1.11 to 3.91)      2.27 (1.24 to 4.16)      1.47 (0.83 to 2.60)      1.86 (1.05 to 3.28)      0.378          5               Y                         P for trend
  Jack et al, 2003 [@pmed.1001376-Jack1]                    NR                     32818                         any                                                                                                             1.00 (0.99 to 1.02)     0.2048          4               N        
  Jack et al, 2006 [@pmed.1001376-Jack2]                    338                     695             48.63        any                 1.00             1.24 (0.76 to 2.02)      0.76 (0.46 to 1.26)      0.98 (0.60 to 1.59)      0.68 (0.41 to 1.14)     0.0978          6               Y         Subset of Jack et al (2003) pop, p for trend
  Jones et al,2008 [@pmed.1001376-Jones1]                  13857                   34923            39.68        any                                                                                                             0.99 (0.99 to 1.00)     \<0.01          4               N        
  Rich et al, 2011(1) [@pmed.1001376-Rich2]                12079                   59592            20.27        any                 1.00             1.08 (1.01 to 1.16)      1.12 (1.04 to 1.20)      1.12 (1.04 to 1.20)      1.02 (0.95 to 1.09)      0.80           5             Y(S)                        P for trend
  Hui et al, 2005 [@pmed.1001376-Hui1]                      NR                      526                          any                  52                       62                       51                       55                       55              0.84           2               N                       Univariable rate
  Stevens et al, 2009 [@pmed.1001376-Stevens3]              222                     555             40.00        any                 1.0                0.8 (0.4 to 1.5)         0.6 (0.3 to 1.2)         0.9 (0.5 to 1.6)         0.7 (0.4 to 1.3)      \>0.05          2               N                   Hosp pop, univariable OR
  Berglund et al, 2010 [@pmed.1001376-Berglund1]            863                    3369             25.62       NSCLC        0.91 (0.67 to 1.22)                               1.12 (0.93 to 1.36)                                       1.00              NR            6               Y        
  Erridge et al, 2002 [@pmed.1001376-Erridge2]              824                    3177             25.94   NSCLC/unknown            1.00             0.94 (0.70 to 1.26)      1.04 (0.79 to 1.38)      1.33 (1.01 to 1.75)      1.13 (0.84 to 1.51)      0.10           6               Y        
  Mahmud et al, 2003 [@pmed.1001376-Mahmud1]               1265                    4451             28.42       NSCLC                26.1                                              29.0                                              29.9              NR            2               N                       Univariable rate
  Cartman et al, 2002 [@pmed.1001376-Cartman1]              693                    2448             28.31       SCLC                 37.1                                                                                                39.5              NR            1               N                       Univariable rate

Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in [Tables 1](#pmed-1001376-t001){ref-type="table"}--[4](#pmed-1001376-t004){ref-type="table"} in the column entitled "No. of SEP groups." Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.

CI, confidence interval; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position; UHCS, universal health care system.

10.1371/journal.pmed.1001376.t010

###### Likelihood of receipt of radiotherapy by SEP group (non-universal health care systems).

![](pmed.1001376.t010){#pmed-1001376-t010-10}

  Study                                           No. Receiving Radio   Cohort No./No. Eligible   Rate      Stage     Histology   OR/rate in Q1 (95% CI)   OR/rate in Q2 (95% CI)   OR/rate in Q3 (95% CI)   OR/rate in Q4 (95% CI)   OR/rate in Q5 (95% CI)         P value          Quality Score   Meta-analysis       Further information
  ---------------------------------------------- --------------------- ------------------------- ------- ----------- ----------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ---------------------- --------------- --------------- ------------------------------
  Bradley et al, 2008 [@pmed.1001376-Bradley1]            950                    2348             40.46   I,II,IIIa     NSCLC              1.00                                                                                        0.97 (0.79 to 1.19)            \>0.05                4               Y        
  Ou et al, 2008 [@pmed.1001376-Ou1]                     2779                    19700            14.11       I         NSCLC              11.7                     12.6                     14.7                     16.5                     16.6                  \<0.001                2               N             Univariable analysis
  Smith et al, 1995 [@pmed.1001376-Smith1]               1323                    2813             47.03     local       NSCLC                                                                                                          0.95 (0.83 to 1.09)           \>0.001                5               N        
  Hardy et al, 2009 [@pmed.1001376-Hardy1]               43519                   51243            84.93    III,IV       NSCLC              1.00             1.01 (0.96 to 1.07)                               0.93 (0.88 to 0.99)      0.88 (0.82 to 0.93)     0.05, \<0.05, \<0.05         5               Y         Individual p-values reported
  Hayman et al, 2007 [@pmed.1001376-Hayman1]             6436                    11084            58.07      IV         NSCLC      1.48 (1.17 to 1.87)      1.50 (1.17 to 1.91)      1.32 (1.01 to 1.72)      1.25 (0.93 to 1.69)              1.00                  \<0.001                5             Y(S)       
  Smith et al, 1995 [@pmed.1001376-Smith1]               1438                    2396             60.02    distant      NSCLC                                                                                                          1.00 (0.90 to 1.12)           \>0.001                5               N        
  Yang et al, 2010 [@pmed.1001376-Yang1]                  NR                      NR                         ??          any               32.0                     32.1                                              31.4                     33.1                    0.02                 2               N             Univariable analysis

Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in [Tables 1](#pmed-1001376-t001){ref-type="table"}--[4](#pmed-1001376-t004){ref-type="table"} in the column entitled "No. of SEP groups." Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.

CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; pop, population; SE, standard error; SEP, socioeconomic position.

Overall, no association between SEP and receipt of radiotherapy was seen in the meta-analysis of the seven studies with non-overlapping populations selected for inclusion (OR = 0.99 \[95% CI 0.86 to 1.14\], p = 0.89, I^2^ = 54%) ([Figure 4](#pmed-1001376-g004){ref-type="fig"}), or when all nine studies were included (OR = 0.95 \[95% CI 0.85 to 1.06\], p = 0.40, I^2^ = 71%) ([Figure S4](#pmed.1001376.s004){ref-type="supplementary-material"}). A significant association was seen for non-UHCS studies but only two studies were included here, each looking at different stage patients.

![Meta-analysis of odds of receipt of radiotherapy in low versus high SEP.\
CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.](pmed.1001376.g004){#pmed-1001376-g004}

Treatment Type not Specified {#s3e}
----------------------------

Seven papers (eight study populations) examined receipt of unspecified treatment, and three papers considered receipt of unspecified curative treatment in three populations ([Tables 11](#pmed-1001376-t011){ref-type="table"}--[13](#pmed-1001376-t013){ref-type="table"}). In the meta-analysis of five non-overlapping studies, low SEP was associated with a lower likelihood of receiving unspecified treatment (OR = 0.78 \[95% CI 0.74 to 0.83\], p\<0.001, I^2^ = 0) ([Figure 5](#pmed-1001376-g005){ref-type="fig"}). This was also seen when studies with overlapping populations were included (OR = 0.80 \[95% CI 0.77 to 0.84\], p\<0.001, I^2^ = 17%) ([Figure S5](#pmed.1001376.s005){ref-type="supplementary-material"}).

![Meta-analysis of odds of receipt of unspecified treatment in low versus high SEP.\
CI, confidence interval; OR, odds ratio; SE, standard error; SEP, socioeconomic position.](pmed.1001376.g005){#pmed-1001376-g005}

10.1371/journal.pmed.1001376.t011

###### Likelihood of receipt of any type of unspecified treatment by SEP group (universal health care systems).

![](pmed.1001376.t011){#pmed-1001376-t011-11}

  Study                                             No. Receiving Treatment   Cohort No./No. Eligible   Rate    Histology   OR/Rate in Q1 (95% CI)   OR/Rate in Q2 (95% CI)   OR/Rate in Q3 (95% CI)   OR/Rate in Q4 (95% CI)   OR/Rate in Q5 (95% CI)     p-Value      Quality Score   Meta-Analysis                        Further Information
  ------------------------------------------------ ------------------------- ------------------------- ------- ----------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ -------------- --------------- --------------- ----------------------------------------------------------------
  Crawford et al, 2009 [@pmed.1001376-Crawford1]             19667                     34923            56.32      any               1.00             0.91 (0.86 to 0.97)                                0.82(0.77 to 0.88)      0.79 (0.74 to 0.84)        \<0.01            4               Y                  Individual p-values, all reported as \<0.01
  Erridge et al, 2009 [@pmed.1001376-Erridge1]               2186                      3833             57.03      any         1.3 (1.1 to 1.5)                                                                                          1.00               \<0.05            4             Y(S)                             Scottish population
  Erridge et al, 2009 [@pmed.1001376-Erridge1]               1372                      2073             66.18      any         1.3 (1.1 to 1.7)                                                                                          1.00               \<0.05            4             Y(S)                             Canadian population
  Jack et al, 2003 [@pmed.1001376-Jack1]                      NR                       32818                       any                                                                                                           0.98 (0.96 to 0.99)        0.0091            4               N        
  Jack et al, 2006 [@pmed.1001376-Jack2]                      414                       695             59.57      any               1.00             0.91 (0.53 to 1.55)      0.69 (0.40 to 1.19)      0.57 (0.34 to 0.97)      0.65 (0.37 to 1.13)         0.03             6               Y              Subset of Jack et al (2003) population, p for trend
  Stevens et al, 2007 [@pmed.1001376-Stevens1]                285                       565             50.44      any               1.0                                                                                           0.9 (0.6 to 1.5)         0.773             3             Y(S)                             Hospital population
  Mahmud et al, 2003 [@pmed.1001376-Mahmud1]                 2678                      4451             60.17     NSCLC              1.0                                         0.9 (0.8 to 1.1)                                  1.0 (0.8 to 1.2)      0.39, 0.958          4             Y(S)        Odds of NOT receiving treatment---individual p-values reported
  Mahmud et al, 2003 [@pmed.1001376-Mahmud1]                  694                      1002             69.26     SCLC               1.0                                         1.0 (0.6 to 1.5)                                  0.8 (0.5 to 1.3)      0.888, 0.358         4             Y(S)        Odds of NOT receiving treatment---individual p-values reported

Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in [Tables 1](#pmed-1001376-t001){ref-type="table"}--[4](#pmed-1001376-t004){ref-type="table"} in the column entitled "No. of SEP groups." Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.

CI, confidence interval; NR, not reported; OR, odds ratio; SEP, socioeconomic position; UHCS, universal health care system.

10.1371/journal.pmed.1001376.t012

###### Likelihood of receipt of any type of unspecified treatment by SEP group (non-universal health care systems).

![](pmed.1001376.t012){#pmed-1001376-t012-12}

  Study                                       No. Receiving Treatment   Cohort No./No. Eligible   Rate    Histology   OR/Rate in Q1 (95% CI)   OR/Rate in Q2 (95% CI)   OR/Rate in Q3 (95% CI)   OR/Rate in Q4 (95% CI)   OR/Rate in Q5 (95% CI)   p-Value   Quality Score   Meta-Analysis        Further Information
  ------------------------------------------ ------------------------- ------------------------- ------- ----------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ --------- --------------- --------------- -------------------------------
  Ou et al, 2008 [@pmed.1001376-Ou1]                   18216                     19700            92.47     NSCLC              94.7                     94.1                     92.2                     91.9                     87.2            \<0.001         2               N         Stage I. Univariable analysis
  Smith et al, 1995 [@pmed.1001376-Smith1]             1697                      2396             70.83     NSCLC                                                                                                          1.00 (0.91 to 1.11)     \>0.001         5               N                 Distant stage
  Smith et al, 1995 [@pmed.1001376-Smith1]             2343                      2813             83.29     NSCLC                                                                                                          1.00 (0.88 to 1.13)     \>0.001         5               N                  Local stage

Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in [Tables 1](#pmed-1001376-t001){ref-type="table"}--[4](#pmed-1001376-t004){ref-type="table"} in the column entitled "No. of SEP groups." Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.

CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; pop, population; SE, standard error; SEP, socioeconomic position.

10.1371/journal.pmed.1001376.t013

###### Likelihood of receipt of any type of unspecified curative treatment by SEP group (universal health care systems).

![](pmed.1001376.t013){#pmed-1001376-t013-13}

  Study                                           No. Receiving Treatment   Cohort No. / No. Eligible   Rate/ Eligible Rate   Histology   OR/Rate in Q1 (95% CI)   OR/Rate in Q2 (95% CI)   OR/Rate in Q3 (95% CI)   OR/Rate in Q4 (95% CI)   OR/Rate in Q5 (95% CI)          p-Value           Quality Score   Meta-Analysis                                 Further Information
  ---------------------------------------------- ------------------------- --------------------------- --------------------- ----------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ --------------- --------------- ---------------------------------------------------------------------------------
  Erridge et al, 2009 [@pmed.1001376-Erridge1]              548                       3833                     14.30             any         1.1(0.9 to 1.4)                                                                                           1.00                    \>0.05                 4             Y (S)                      Scottish pop -- subset of Gregor et al (2001) pop
  Erridge et al, 2009 [@pmed.1001376-Erridge1]              546                       2073                     26.34             any         1.4(1.1 to 1.8)                                                                                           1.00                    \<0.05                 4               Y                                          Canadian pop
  Gregor et al, 2001 [@pmed.1001376-Gregor1]                627                     3855/1423               16.26/44.06          any               1.00             1.14 (0.72 to 1.80)      1.07 (0.69 to 1.66)      0.95 (0.62 to 1.47)      0.77 (0.51 to 1.16)              0.25                  6               Y                                    Eligible  =  early stage
  Stevens et al, 2008 [@pmed.1001376-Stevens2]              109                        565                     19.29             any               1.0                3.1 (1.0 to 9.7)         1.4 (0.4 to 4.4)         1.1 (0.4 to 0.3)         0.6 (0.2 to 1.8)      0.05, 0.60, 0.86, 0.40         5               Y         Hospital pop - subset of Stevens et al (2007) pop, individual p-values reported

Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in [Tables 1](#pmed-1001376-t001){ref-type="table"}--[4](#pmed-1001376-t004){ref-type="table"} in the column entitled "No. of SEP groups." Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position, Q5, low socioeconomic position.

CI, confidence interval; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position; UHCS, universal health care system.

When the surgery, chemotherapy, and radiotherapy papers included in the separate treatment meta-analyses in this systematic review were analysed together to produce an overall summary effect meta-analysis OR, a similar result was seen, with low SEP associated with a lower likelihood of receiving any type of treatment. This was found when including only studies with non-overlapping populations (OR = 0.79 \[95% CI 0.73 to 0.86\], p\<0.001, I^2^ = 77%) ([Figure S6](#pmed.1001376.s006){ref-type="supplementary-material"}) and when including all eligible studies (OR = 0.80 \[95% CI 0.75 to 0.86\], p\<0.001, I^2^ = 82%) ([Figure S7](#pmed.1001376.s007){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Principal Findings {#s4a}
------------------

To our knowledge, this is the first systematic review and meta-analysis examining socioeconomic inequalities in receipt of lung cancer treatment. It shows an association between low SEP and reduced likelihood of receipt of any type of treatment, surgery, and chemotherapy. The results were generally consistent across different health care systems.

Interpretation of Results {#s4b}
-------------------------

Surgery is suitable only for patients with early-stage NSCLC, and it has been suggested that patients with cancer in a lower SEP are more likely to present later and with later-stage disease [@pmed.1001376-Dalton1]. This may help explain why socioeconomic inequalities in receipt of surgery are observed in some studies. However, presentation with later-stage cancer in lower SEP patients has not been consistently observed [@pmed.1001376-Berglund1]. In this review, when receipt of treatment was examined in studies of early-stage patients only (from non-UHCS studies), low SEP remained associated with reduced likelihood of surgery. Thus, the association between SEP and receipt of surgery appears to be independent of stage. Similar results were seen for NSCLC studies in both health care systems.

Receipt of treatment may also be influenced by clinical suitability for treatment, and socioeconomic differences in the number of co-morbidities present may explain socioeconomic inequalities in treatment. In the three UHCS studies that took co-morbidity into account, SEP was not associated with receipt of surgery [@pmed.1001376-Rich1],[@pmed.1001376-Berglund2] or of any treatment [@pmed.1001376-Stevens1] when the trend across SEP groups was examined, suggesting that co-morbidity may be a potential mediator of socioeconomic inequalities in treatment in UHCSs. However, most of the non-UHCS studies did include co-morbidity as a confounder, and socioeconomic inequalities in treatment were still observed, suggesting that there may be differences between health care systems here.

Strengths and Weaknesses of the Review and of the Available Evidence {#s4c}
--------------------------------------------------------------------

This is one of the first equity reviews published [@pmed.1001376-Welch1],[@pmed.1001376-Thomas1], the first systematic review of the literature on intervention-generated inequalities in lung cancer treatment to our knowledge, and the first cancer equity review to include a meta-analysis. Extensive searches were carried out to identify studies. However, it is possible that not all relevant studies were obtained.

The included studies reported observational data only. The suitability of meta-analysis for observational studies has been questioned, as it may produce precise but spurious results [@pmed.1001376-Egger1]. Examining the possible sources of heterogeneity by conducting sensitivity analyses across different sub-groups may be less prone to bias than calculating an overall summary effect [@pmed.1001376-Egger1]. Here, although an overall summary effect OR was calculated, heterogeneity was taken into account. Separate analyses by type of treatment were carried out, with further stratification by stage and histology. Universal and non-UHCSs were examined separately and random effects rather than fixed effects meta-analyses were conducted. These precautions did not change the overall pattern of results seen.

Significant heterogeneity remained in some cases, which could be considered a limitation, although this is not surprising because of the characteristics of the studies included. For studies examining receipt of chemotherapy and radiotherapy it was generally not possible to differentiate between curative and palliative treatment and, if patterns of care differ for these by SEP, this might explain the high degree of heterogeneity seen. However, although there is some suggestion that heterogeneity can be considered high at \>50% [@pmed.1001376-The1], when confidence intervals were calculated these were wide, so it was difficult to be confident about the degree of heterogeneity present [@pmed.1001376-Ioannidis1].

[Results](#s3){ref-type="sec"} for receipt of radiotherapy differed in the non-UHCS sub-group compared to overall but, as only two studies were included in this sub-group, it is difficult to be sure that different patterns of receipt of radiotherapy by SEP are due to differences in health care system.

Many of the non-UHCS studies used overlapping population sub-groups from the SEER database. There was also population overlap between some UHCS datasets. We attempted to include only substantially non-overlapping datasets within the final meta-analyses to ensure independence of results. A judgement had to be made as to which was the best-quality and most appropriate paper to include, but sensitivity analyses using different inclusion combinations ([Figure S8](#pmed.1001376.s008){ref-type="supplementary-material"}) did not change the overall findings, nor did including all suitable studies regardless of population overlap ([Figures S1](#pmed.1001376.s001){ref-type="supplementary-material"}, [S3](#pmed.1001376.s003){ref-type="supplementary-material"}, [S4](#pmed.1001376.s004){ref-type="supplementary-material"}, [S5](#pmed.1001376.s005){ref-type="supplementary-material"}, [S7](#pmed.1001376.s007){ref-type="supplementary-material"}).

Included papers contained data for patients diagnosed between 1978 and 2008. As treatment guidance has changed over time, older studies may be less applicable to current clinical practice. However, the majority of included studies were published within the last five years, and sensitivity analyses excluding studies published prior to 2000 did not change the overall findings.

Various measures of SEP were used, and these were categorised differently---an acknowledged problem in equity reviews [@pmed.1001376-Ogilvie1]. All but one study measured SEP at the area level. This is a further limitation, as area-based measures of SEP are unlikely to be accurate markers of individual-level circumstances and access to resources [@pmed.1001376-Adams1]. Area-based measures of SEP can be calculated using address, making them easy to add to disease registers, such as those used in many of the studies synthesised here. However, the reliance on area-based markers of SEP may underestimate the strength of the true association between SEP and receipt of treatment.

Not all studies reported details of stage and histology---both of which influence treatment type---and very few UHCS studies took co-morbidity into account. Thus, the ORs used in the meta-analyses were not consistently adjusted for the same covariates. However, we attempted to take these factors into account in the quality scores and by conducting subgroup sensitivity analyses. Examining only high-quality studies did not alter our findings nor did sensitivity analyses, although consequent reduction in numbers did result in loss of significance in some analyses, potentially due to lack of power to detect differences.

In order to conduct meta-analysis it is necessary to compare the odds of treatment in the lowest-SEP group with the odds in the highest, which simplifies what may be a complex relationship across SEP groups. However, studies that reported a change in odds ratios across the SEP categories, and thus explored trends in receipt of treatment, generally supported the overall findings of the review.

A number of existing tools suitable for assessing cohort study quality were considered [@pmed.1001376-SIGN1],[@pmed.1001376-Vandenbroucke1]. However, none of these tools was entirely appropriate for the type of studies included and, as has been done in previous reviews [@pmed.1001376-Slatore1],[@pmed.1001376-Olsson1], we devised a unique tool, adapting and utilising aspects of other available tools. This approach has the benefit of producing a quality tool that is highly specific for the type of studies examined.

As with any systematic review, we are unable to exclude the possibility of publication bias. Studies reporting null findings are less likely to be published or, if they are published, not to report numerical outcomes [@pmed.1001376-The1]. A funnel plot to assess potential publication bias did not show obvious bias ([Figure S9](#pmed.1001376.s009){ref-type="supplementary-material"}). However, a number of papers recovered in the search included SEP in the description of the study population but did not report receipt of treatment by SEP [@pmed.1001376-Grose1]--[@pmed.1001376-Riaz1]. Study authors were contacted and asked to provide further information, but only one supplied the requested data [@pmed.1001376-Riaz1]. It is likely that SEP was not significantly associated with receipt of treatment in the other studies, but this was not always clearly reported. However, publication bias is thought to be less important than other sources of bias, such as confounding, in meta-analyses of observational studies [@pmed.1001376-Egger1].

Implications for Policy and Practice {#s4d}
------------------------------------

Socioeconomic inequalities in receipt of treatment may exacerbate socioeconomic inequalities in incidence of lung cancer, which is strongly associated with higher smoking rates in more deprived populations, so may further contribute to the poorer outcomes in lower SEP groups.

Socioeconomic inequalities in treatment may be due to differences in access to care. Within a non-UHCS it might be expected that socioeconomic differences in receipt of treatment would be observed due to income-related differences in health insurance status. Patients with lung cancer in the USA who do not have insurance have been shown to have more limited access to care [@pmed.1001376-Slatore1]. However, as socioeconomic inequalities in receipt of lung cancer treatment were also observed in UHCSs that do not depend on ability to pay and in non-UHCS studies where insurance type was taken into account, this would suggest that other system factors may be contributing to this inequality. The extent to which receipt of treatment is influenced by factors such as patient choice is not known.

Variability at the patient, tumour, system, and individual clinician levels needs to be investigated before clear recommendations for changes to policy and practice can be made.

Future Research {#s4e}
---------------

This review has demonstrated a clear association between lower SEP and reduced likelihood of receiving surgery, chemotherapy, and any type of unspecified treatment for lung cancer. The reasons for these inequalities need to be more thoroughly investigated. Better-quality UHCS studies, including statistical control for co-morbidity and stratification by stage and histology---so that only those patients eligible for a particular treatment are included in the population-denominator---are required. It would also be useful to be able to distinguish between curative and palliative intent of treatment. In non-UHCS, studies in younger populations, examining a range of insurance providers, are required.

Further investigation into the system and patient factors that might contribute to socioeconomic inequalities in receipt of lung cancer care is necessary, to help develop interventions that ensure equitable receipt of appropriate treatment. This should include a quantitative exploration of inequalities at each stage of the care pathway as well as qualitative work exploring reasons for inequality. Inequalities in receipt of treatment may contribute to inequalities in cancer survival and so cohort survival analyses are warranted in order to investigate intervention-generated inequalities in lung cancer outcomes.

Supporting Information {#s6}
======================

###### 

**Meta-analysis of odds of receipt of surgery in low versus high SEP (overlapping populations).** CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.

(TIF)

###### 

Click here for additional data file.

###### 

**Meta-analysis of odds of receipt of surgery for NSCLC in low versus high SEP (non-overlapping populations).** CI, confidence interval; OR, odds ratio; SE, standard error; SEP, socioeconomic position.

(TIF)

###### 

Click here for additional data file.

###### 

**Meta-analysis of odds of receipt of chemotherapy in low versus high SEP (overlapping populations).** CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.

(TIF)

###### 

Click here for additional data file.

###### 

**Meta-analysis of odds of receipt of radiotherapy in low versus high SEP (overlapping populations).** CI = confidence interval, non-UHCS = non-universal health care system, OR = odds ratio, SE = standard error, SEP = socioeconomic position UHCS = universal health care system.

(TIF)

###### 

Click here for additional data file.

###### 

**Sensitivity meta-analysis of odds of receipt unspecified treatment in low versus high SEP (overlapping populations).** CI, confidence interval; OR, odds ratio; SE, standard error; SEP, socioeconomic position.

(TIF)

###### 

Click here for additional data file.

###### 

**Meta-analysis of odds of receipt of any type of treatment in low versus high SEP.** CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.

(TIF)

###### 

Click here for additional data file.

###### 

**Meta-analysis of odds of receipt of any type of treatment in low versus high SEP (overlapping populations).** CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.

(TIF)

###### 

Click here for additional data file.

###### 

**Meta-analysis of odds of receipt of surgery in low versus high SEP (partially-overlapping populations).** CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.

(TIF)

###### 

Click here for additional data file.

###### 

**Funnel plot to assess publication bias.** CI, confidence interval; non-UHCS, non-universal health care system; NSCLC, non-small cell lung cancer; UHCS, universal health care system.

(TIF)

###### 

Click here for additional data file.

###### 

**Full search strategies (MEDLINE and EMBASE).**

(DOC)

###### 

Click here for additional data file.

###### 

**PRISMA checklist.**

(DOC)

###### 

Click here for additional data file.

###### 

**Protocol.**

(DOC)

###### 

Click here for additional data file.

###### 

**Quality score checklist.**

(DOC)

###### 

Click here for additional data file.

CI

:   confidence interval

NSCLC

:   non-small cell lung cancer

OR

:   odds ratio

SCLC

:   small cell lung cancer

SEER

:   National Cancer Institute\'s Surveillance, Epidemiology and End Results

SEP

:   socioeconomic position

UHCS

:   universal health care system
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